The Role of Next-Generation Sequencing in the Management of Patients with Suspected Non-Ischemic Cardiomyopathy after Syncope or Termination of Sudden Arrhythmic Death.

Cardiac arrhythmias and sudden death are frequent in patients with non-ischemic cardiomyopathy and can precede heart failure or additional symptoms where malignant cardiac arrhythmias are mostly the consequence of advanced cardiomyopathy and heart failure. Finding these subgroups and making an early diagnosis could be lifesaving. In our retrospective study, we are presenting arrhythmic types of frequent cardiomyopathies where an arrhythmogenic substrate is less well defined, as in ischemic or structural heart disease. In the period of 2 years, next-generation sequencing (NGS) tests along with standard clinical tests were performed in 208 patients (67 women and 141 men; mean age, 51.2 ± 19.4 years) without ischemic or an overt structural heart disease after syncope or aborted sudden cardiac death. Genetic variants were detected in 34.4% of the study population, with a significant proportion of pathogenic variants (P) (14.4%) and variants of unknown significance (VUS) (20%). Regardless of genotype, all patients were stratified according to clinical guidelines for aggressive treatment of sudden cardiac death with an implantable cardioverter defibrillator (ICD). The P variant identified by NGS serves for an accurate diagnosis and, thus, better prevention and specific treatment of patients and their relatives. Results in our study suggest that targeted sequencing of genes associated with cardiovascular disease is an important addendum for final diagnosis, allowing the identification of a molecular genetic cause in a vast proportion of patients for a definitive diagnosis and a more specific way of treatment. VUS in this target population poses a high risk and should be considered possibly pathogenic in reanalysis.

Mitral Annular Plane Systolic Excursion (MAPSE) as a Predictor of Atrial Fibrillation Recurrence in Patients after Pulmonary Vein Isolation.

Introduction: Catheter ablation (CA) with pulmonary vein isolation (PVI) has become widely used in the past years for the treatment of atrial fibrillation (AF). Mitral annular plane systolic excursion (MAPSE) is the parameter that measures left ventricular longitudinal function, and it appears to be a good early marker of LV dysfunction. It is practically independent of poor image quality. The aim of our study was to analyse the role of echocardiographic variables, especially MAPSE in predicting the outcome of CA in patients with AF. Materials and Methods: We prospectively included 40 patients with paroxysmal and persistent AF that were referred for CA. All patients underwent radiofrequency CA with PVI. Standard transthoracic two-dimensional echocardiography was conducted one day after CA. Demographic data and the patients' characteristics were noted. The endpoint of our study was to estimate the AF recurrence rate diagnosed by ECG within 6 months of the follow-up period. Results: 40 patients, mainly male (67.5%) with an average age of 61.43 ± 8.96 years were included in our study. The majority of patients had paroxysmal AF prior to ablation (77.5%). The AF recurrence rate was 20% after 6 months of follow-up. Lateral MAPSE in the AF-free group was greater than those who relapsed (1.57 ± 0.24 vs. 1.31 ± 0.25; p = 0.012). Patients who remained AF-free after a 6-month follow-up period had a significantly smaller left ventricular volume index (LAVI) than those who relapsed (34.29 ± 6.91 ml/m2 vs. 42.90 ± 8.43 ml/m2; p = 0.05). We found a significant reverse relationship between LAVI and MAPSE (p = 0.020). Conclusion: MAPSE and LAVI present risk factors for AF recurrence, specifically reduced MAPSE and larger LAVI, are related to AF recurrence after CA. In the future, MAPSE could play a significant role when predicting the CA outcome in patients with AF.

Acute total occlusion of the left main coronary artery treated with percutaneous intervention and simultaneous implantation of intra-aortic balloon pump.

Electrocardiographic findings at first medical contact and direct transfer to the catheterization laboratory are important in acute total occlusion of the left main coronary artery. Simultaneous emergency angioplasty and intra-aortic balloon pump implantation might be beneficial in overcoming the patient's most critical hemodynamic instability.

Changes in left ventricular filling in patients with persistent atrial fibrillation.

BACKGROUND: Former studies showed possible interrelationship between altered ventricular filling patterns and atrial fibrillation (AF). HYPOTHESIS: Long term persistent AF has a negative impact on left ventricular filling in patients with preserved ejection fraction of left ventricle. METHODS: Our study was designed as a prospective case control study. We included 40 patients with persistent AF and preserved ejection fraction after successful electrical cardioversion and 43 control patients. Persistent AF was defined as AF lasting more than 4 weeks. Cardiac ultrasound was performed in all patients 24 hours after the procedure. Appropriate mitral flow and tissue Doppler velocities as well as standard echocardiographic measurements were obtained. RESULTS: There were no significant differences between both groups' parameters regarding age, sex, commorbidities or drug therapy. Analysis of mitral flow velocities showed significant increase of E value in AF group (0.96±0.27 vs.0.70±0.14; p = 0.001). Tissue Doppler measurements didn't reveal any differences in early diastolic movement, however there was a statistically significant difference in E/Em values of both groups, respectively (12.0±4.0 vs. 9.0±2.1; p= 0.001). CONCLUSION: Our study shows that in patients with preserved systolic function and persistent AF shortly after cardioversion diastolic ventricular filling patterns are altered mainly due to increased left atrial pressure and not due to impaired diastolic relaxation of left ventricle. Further studies are needed in order to define the interplay between diminished atrial function and impaired ventricular filling.

Optimal timing of electrical cardioversion in patients with persistent atrial fibrillation.

BACKGROUND: Many studies have tried to propose risk factors for atrial fibrillation recurrence after a successful pharmacological or electrical cardioversion. Regarding the duration of atrial fibrillation before electrical cardioversion, only limited data exist. The aim of our study was to investigate the effect of atrial fibrillation duration on long-term sinus rhythm maintenance in patients after successful electrical cardioversion of persistent atrial fibrillation. MATERIAL/METHODS: Three hundred one patients after successful electrical cardioversion were included in the analysis. The patients were followed for 2 years. Electrocardiogram showing atrial fibrillation was considered the study endpoint. RESULTS: After mean observational time of 377±311 days, atrial fibrillation occurred in 168 patients (61.5%). Multivariate logistic regression analysis showed the duration of atrial fibrillation was the only predictor of atrial fibrillation recurrence (OR 1.06; CI 1.00-1.11; P=.036), while amiodarone appeared to protect against atrial fibrillation recurrence OR 0.26; CI 0.07-0.95; P=.041). A Cox proportional hazards multivariate model predicted atrial fibrillation recurrence rate of atrial fibrillation ≥10 months (OR 1.87, CI 1.26 to 2.76, P=.002) and treatment with amiodarone (OR 0.55, CI 0.40-0.76, P=.000). CONCLUSIONS: Atrial fibrillation duration before electric cardioversion is a significant predictor of atrial fibrillation recurrence rate after successful restoration of sinus rhythm. Further studies are needed to clarify the implications of atrial fibrillation duration on sinus rhythm persistence after a successful cardioversion.

High homocysteine levels predict the recurrence of atrial fibrillation after successful electrical cardioversion.

Recent data suggest that elevated plasma levels of homocysteine could be associated with atrial fibrillation (AF). The aim of our study was to investigate whether elevated plasma Hcy levels were predictive of the recurrence rate of AF after successful electrical cardioversion. Eighty-three patients (63 +/- 12 years, 61.4% men) with persistent AF lasting at least 7 days were included after successful electrical cardioversion. Echocardiography and plasma homocysteine assay were performed prior to cardioversion and patient baseline characteristics were obtained. Patients were monitored for a period of 18 months. The patients were divided into two groups using a cut-off value for the last quartile of plasma homocysteine concentration (> 14.4 micromol/L). Kaplan Meier analysis showed a statistically significant difference in AF recurrence rates between both groups after 18 months (P = 0.02, log rank test). Cox proportional hazards multivariate analysis showed that predictors of AF recurrence were the duration of AF (OR 1.05, 95% CI 1.02-1.08, P = 0.00), treatment with amiodarone (OR 0.39, 95% CI 0.21-0.72, P = 0.00), and homocysteine level < or = 14.4 micromol/L (OR 0.39, 95% CI 0.21-0.73, P = 0.00). We found that the homocysteine levels determined prior to electrical cardioversion can predict recurrence of AF after successful restoration of sinus rhythm.

Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardioversion.

BACKGROUND: Amiodarone is effective in preventing atrial fibrillation (AF). Recently, the possible antiarrhythmic effects of statins have been revealed. We hypothesized that statins added to amiodarone may reduce the recurrence rate of AF after successful electrical cardioversion (EC). MATERIAL/METHODS: The retrospective analysis included 198 consecutive patients (63+/-10 years; 56% men) with persistent AF (lasting at least one month, average 5.8+/-7.6 months) who underwent successful EC. All patients were put on long-time treatment with amiodarone according to standard protocol prior to EC; 50 patients (25%) also received statin therapy. AF recurrence was recorded in the following two years. RESULTS: Recurrence of AF occurred less frequently in patients receiving statins and amiodarone than in those receiving amiodarone only (24 (48.0%) vs. 95 (64.1%) patients). The mean AF-free period was significantly prolonged in the statin-amiodarone group (513+/-38 days vs. 374+/-25 days, log rank test P<0.02). Cox univariate analysis showed that treatment with statins and the duration of AF before EC were significant predictors for AF recurrence. After adjustment for other potential confounders, statin therapy proved to be a statistically significant predictor of sinus rhythm maintenance (adjusted OR 0.60, 95% CI 0.38 to 0.93, P=0.02). CONCLUSIONS: Our study shows that adding statins to amiodarone significantly decreases the recurrence rate of AF after successful EC in patients with persistent AF. Our findings urge for prospective randomized studies to be performed in order to confirm these results and elucidate the role of statins in AF prevention.

Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion.

Recent data have shown that statins can help prevent atrial fibrillation (AF). We hypothesized that statins vary in their ability to prevent AF after successful electrical cardioversion (EC).Sixty-five patients (29 receiving atorvastatin and 36 receiving simvastatin) who had undergone successful EC for persistent AF were included in the study. They received statins at least one month before EC, and continued the treatment through 2 years of follow-up. The statins they received were selected independently by their attending physicians. In the follow-up period, AF reoccurred in 11 (38.0%) patients of the atorvastatin group and in 24 (66.7%) patients of the simvastatin group. Using a logistic regression model, the unadjusted odds ratio (OR) of having an AF recurrence for patients on atorvastatin versus those on simvastatin was 0.31 (95% CI 0.11-0.85, P = 0.02). After adjustment for other potentially confounding variables (age, sex, hypertension, diabetes, ischemic heart disease, echocardiographic characteristics, and therapy), treatment with atorvastatin retained its significance for maintaining sinus rhythm in a multivariate model (OR 0.20, CI 0.04 to 0.98, P < 0.05).Our study suggests that atorvastatin and simvastatin exert different effects on the AF recurrence rate after successful EC. Larger prospective randomized trials are needed to definitively evaluate the role of different statins in patients with AF, especially on AF recurrence after EC.